ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Plexium launches to degrade proteins

by Lisa M. Jarvis
October 19, 2019 | APPEARED IN VOLUME 97, ISSUE 41

 

Plexium, a biotech firm devoted to finding small molecules that induce protein degradation, has launched with $28 million from its first formal funding round. The San Diego–based firm will use DNA-encoded libraries to conduct cell-based screens for molecules that can prompt E3 ligases to raise or lower levels of specific proteins. Plexium’s first goal is to modulate proteins implicated in cancer and neurodegenerative diseases.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment